Catalent behind Novo Nordisk's supply issues, says media

An FDA inspection gone awry at contract manufacturer Catalent's Belgian facility is allegedly behind Novo Nordisk's supply issues for its obesity drug, Wegovy, which was recently launched on the US market.

Concerns about acceptable production practices at Catalent's syringe filling facility is the reason why Novo Nordisk is now only expected to be able to fully meet Wegovy demand in the second half of 2022, according to media Bioprocess International.

Catalent confirms that an inspection by the US Food and Drug Administration (FDA) resulted in an FDA Form 483, which is issued to a firm's management following an inspection during which objectionable conditions have been observed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs